Arian Lasocki - Academia.edu (original) (raw)

Papers by Arian Lasocki

Research paper thumbnail of Memory loss and confusion: Answer

Journal of Clinical Neuroscience, 2019

Research paper thumbnail of Improving the diagnosis of radiation necrosis after stereotactic radiosurgery to intracranial metastases with conventional MRI features: a case series

Cancer Imaging

Background The distinction between true disease progression and radiation necrosis after stereota... more Background The distinction between true disease progression and radiation necrosis after stereotactic radiosurgery to intracranial metastases is a common, but challenging, clinical scenario. Improvements in systemic therapies are increasing the importance of this distinction. A variety of imaging techniques have been investigated, but the value of any individual technique is limited. Case presentation Assessment should extend beyond simply the appearances of the lesion at a given timepoint, but also consider local anatomy and lesion evolution. Firstly, enlargement of a metastasis is affected by local anatomical boundaries, such as the dural reflections or cerebrospinal fluid spaces. In contrast, the radiation dose administered with stereotactic radiosurgery does not respect these anatomical boundaries and is largely concentric around the treated lesion. Therefore, new, non-contiguous enhancement across such a boundary can be confidently attributed to radiation necrosis. Secondly, th...

Research paper thumbnail of Part 1: Imaging findings of common immune checkpoint inhibitor‐related adverse effects

Journal of Medical Imaging and Radiation Oncology, 2022

Over the last decade or so, immunotherapy and in particular immune checkpoint inhibitors have bec... more Over the last decade or so, immunotherapy and in particular immune checkpoint inhibitors have become common in the treatment of numerous cancers and have revolutionised oncology. The unique mechanisms of these agents has resulted in novel tumour response patterns and also new drug-related toxicities, both of which can have specific findings on imaging. The widespread and increasing use of these agents means these findings are now encountered across many radiology practices beyond just specialist oncology units. This pictorial essay aims to describe and illustrate imaging findings associated with common and important immune-related adverse events as a result of treatment with immune checkpoint inhibitors.

Research paper thumbnail of Neuro-Oncology and Radiogenomics: Time to Integrate?

American Journal of Neuroradiology, 2020

Radiogenomics aims to predict genetic markers based on imaging features. The critical importance ... more Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.

Research paper thumbnail of Ischaemic stroke in the setting of glioblastoma: A case series and review of the literature

The Neuroradiology Journal, 2016

Ischaemic strokes are an uncommon occurrence in the setting of glioblastoma, and clinically chall... more Ischaemic strokes are an uncommon occurrence in the setting of glioblastoma, and clinically challenging due to co-existing deficits from the tumour, but important to consider as a possible cause of clinical deterioration. Modern therapies and their associated improvements in survival may lead to a greater overall incidence. The possible underlying causes of ischaemia are multiple, and several factors may contribute in a given patient. This review discusses the causative mechanisms of ischaemic strokes in the setting of glioblastoma, with some illustrative cases.

Research paper thumbnail of Immune checkpoint inhibitor related adverse effects and imaging findings

Research paper thumbnail of Secondary Central Nervous System Manifestations of Haematological Malignancies

Research paper thumbnail of Prospective comparison of post-contrast MPRAGE and T1-SPACE in patients with metastatic melanoma

Research paper thumbnail of Incidence of Radiation Necrosis and Potential Risk Factors in Patients Treated with Fractionated Stereotactic Radiosurgery for Intact Intracranial Metastases

Research paper thumbnail of Investigating the role of delayed contrast MRI to differentiate radiation necrosis from tumour recurrence in brain metastases after stereotactic radiosurgery

Research paper thumbnail of T2-SPACE imaging of the cauda equina for the assessment of leptomeningeal metastatic disease

Journal of Clinical Neuroscience

Research paper thumbnail of The preoperative MRI assessment of adult intracranial diffuse gliomas

All work was performed in collaboration with co-investigators as named. The applicant's contribut... more All work was performed in collaboration with co-investigators as named. The applicant's contribution was greater than 50% for all publications.  None of this work has been previously submitted for other qualifications.  No third party editorial assistance was provided.  The thesis is fewer than the maximum word limit in length.

Research paper thumbnail of The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy

Magnetic resonance spectroscopy (MRS) provides a non-invasive means of determining isocitrate deh... more Magnetic resonance spectroscopy (MRS) provides a non-invasive means of determining isocitrate dehydrogenase (IDH) status. Determination of 2-hydroxyglutarate (2-HG) presence through MRS is a means of determining IDH status; however, differences may be seen by grade. The goal of this paper is to perform a diagnostic test accuracy (DTA) meta-analysis on 2-HG MRS for IDH status in both lower-grade glioma (LGG) and glioblastoma (GBM) in preoperative patients. A systematic review and meta-analysis were performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Diagnostic Test Accuracy guidelines. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies 2. The search was up to date as of 09/02/2021. Nine English-language journal articles were included. The meta-analysis found a pooled sensitivity of 93% (95% CI 58–99%) and specificity of 84% (95% CI 51–96%) for LGG (n= 181). For GBM (n= 77), the pooled sensitivity wa...

Research paper thumbnail of Hypertrophic olivary degeneration: anatomy, aetiology and neuroimaging

Poster: "2017 ASM / R-0080 / Hypertrophic olivary degeneration: anatomy, aetiology and neuro... more Poster: "2017 ASM / R-0080 / Hypertrophic olivary degeneration: anatomy, aetiology and neuroimaging" by: "K. Ravindran, A. Lasocki, F. Gaillard; Melbourne/AU"

Research paper thumbnail of Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research

American Journal of Neuroradiology

There is a growing understanding of the prognostic importance of non-contrast-enhancing tumor in ... more There is a growing understanding of the prognostic importance of non-contrast-enhancing tumor in glioblastoma, and recent attempts at more aggressive management of this component using neurosurgical resection and radiosurgery have been shown to prolong survival. Optimizing these therapeutic strategies requires an understanding of the features that can distinguish non-contrast-enhancing tumor from other processes, in particular vasogenic edema; however, the limited and heterogeneous manner in which it has been defined in the literature limits clinical translation. This review covers pertinent literature on our growing understanding of non-contrast-enhancing tumor and focuses on key conventional MR imaging features for improving its delineation. Such features include subtle differences in the degree of FLAIR hyperintensity, gray matter involvement, and focal mass effect. Improved delineation of tumor from edema will facilitate more aggressive management of this component and potentially realize associated survival benefits.

Research paper thumbnail of Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Journal for ImmunoTherapy of Cancer

BackgroundMelanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity... more BackgroundMelanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab–nivolumab have similar intracranial response rates (50%–55%), central nervous system (CNS) resistance to BRAF-MEK inhibitors (BRAF-MEKi) usually occurs around 6 months, and durable responses are only seen with combination immunotherapy. We sought to investigate the utility of ipilimumab–nivolumab after MBM progression on BRAF-MEKi and identify mechanisms of resistance.MethodsPatients who received first-line ipilimumab–nivolumab for MBMs or second/third line ipilimumab–nivolumab for intracranial metastases with BRAFV600 mutations with prior progression on BRAF-MEKi and MRI brain staging from March 1, 2015 to June 30, 2018 were included. Modified intracranial RECIST was used to assess response. Formalin-fixed paraffin-embedded samples of BRAFV600 mutant MBMs that were naïve to systemic treatment (n=18) or excised afte...

Research paper thumbnail of Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy

Research paper thumbnail of Correction to: Serum microRNA is a biomarker for post-operative monitoring in glioma

Journal of Neuro-Oncology

Research paper thumbnail of The Imaging of Immunotherapy-Related Hypophysitis and Other Pituitary Lesions in Oncology Patients

Research paper thumbnail of Serum microRNA is a biomarker for post-operative monitoring in glioma

Journal of Neuro-Oncology

Research paper thumbnail of Memory loss and confusion: Answer

Journal of Clinical Neuroscience, 2019

Research paper thumbnail of Improving the diagnosis of radiation necrosis after stereotactic radiosurgery to intracranial metastases with conventional MRI features: a case series

Cancer Imaging

Background The distinction between true disease progression and radiation necrosis after stereota... more Background The distinction between true disease progression and radiation necrosis after stereotactic radiosurgery to intracranial metastases is a common, but challenging, clinical scenario. Improvements in systemic therapies are increasing the importance of this distinction. A variety of imaging techniques have been investigated, but the value of any individual technique is limited. Case presentation Assessment should extend beyond simply the appearances of the lesion at a given timepoint, but also consider local anatomy and lesion evolution. Firstly, enlargement of a metastasis is affected by local anatomical boundaries, such as the dural reflections or cerebrospinal fluid spaces. In contrast, the radiation dose administered with stereotactic radiosurgery does not respect these anatomical boundaries and is largely concentric around the treated lesion. Therefore, new, non-contiguous enhancement across such a boundary can be confidently attributed to radiation necrosis. Secondly, th...

Research paper thumbnail of Part 1: Imaging findings of common immune checkpoint inhibitor‐related adverse effects

Journal of Medical Imaging and Radiation Oncology, 2022

Over the last decade or so, immunotherapy and in particular immune checkpoint inhibitors have bec... more Over the last decade or so, immunotherapy and in particular immune checkpoint inhibitors have become common in the treatment of numerous cancers and have revolutionised oncology. The unique mechanisms of these agents has resulted in novel tumour response patterns and also new drug-related toxicities, both of which can have specific findings on imaging. The widespread and increasing use of these agents means these findings are now encountered across many radiology practices beyond just specialist oncology units. This pictorial essay aims to describe and illustrate imaging findings associated with common and important immune-related adverse events as a result of treatment with immune checkpoint inhibitors.

Research paper thumbnail of Neuro-Oncology and Radiogenomics: Time to Integrate?

American Journal of Neuroradiology, 2020

Radiogenomics aims to predict genetic markers based on imaging features. The critical importance ... more Radiogenomics aims to predict genetic markers based on imaging features. The critical importance of molecular markers in the diagnosis and management of intracranial gliomas has led to a rapid growth in radiogenomics research, with progressively increasing complexity. Despite the advances in the techniques being examined, there has been little translation into the clinical domain. This has resulted in a growing disconnect between cutting-edge research and assimilation into clinical practice, though the fundamental goal is for these techniques to improve patient care. The goal of this review, therefore, is to discuss possible clinical scenarios in which the addition of radiogenomics may aid patient management. This includes facilitating patient counseling, determining optimal patient management when complete molecular characterization is not possible, reclassifying tumors, and overcoming some of the limitations of histologic assessment. The review also discusses considerations for selecting relevant radiogenomic features based on the clinical setting.

Research paper thumbnail of Ischaemic stroke in the setting of glioblastoma: A case series and review of the literature

The Neuroradiology Journal, 2016

Ischaemic strokes are an uncommon occurrence in the setting of glioblastoma, and clinically chall... more Ischaemic strokes are an uncommon occurrence in the setting of glioblastoma, and clinically challenging due to co-existing deficits from the tumour, but important to consider as a possible cause of clinical deterioration. Modern therapies and their associated improvements in survival may lead to a greater overall incidence. The possible underlying causes of ischaemia are multiple, and several factors may contribute in a given patient. This review discusses the causative mechanisms of ischaemic strokes in the setting of glioblastoma, with some illustrative cases.

Research paper thumbnail of Immune checkpoint inhibitor related adverse effects and imaging findings

Research paper thumbnail of Secondary Central Nervous System Manifestations of Haematological Malignancies

Research paper thumbnail of Prospective comparison of post-contrast MPRAGE and T1-SPACE in patients with metastatic melanoma

Research paper thumbnail of Incidence of Radiation Necrosis and Potential Risk Factors in Patients Treated with Fractionated Stereotactic Radiosurgery for Intact Intracranial Metastases

Research paper thumbnail of Investigating the role of delayed contrast MRI to differentiate radiation necrosis from tumour recurrence in brain metastases after stereotactic radiosurgery

Research paper thumbnail of T2-SPACE imaging of the cauda equina for the assessment of leptomeningeal metastatic disease

Journal of Clinical Neuroscience

Research paper thumbnail of The preoperative MRI assessment of adult intracranial diffuse gliomas

All work was performed in collaboration with co-investigators as named. The applicant's contribut... more All work was performed in collaboration with co-investigators as named. The applicant's contribution was greater than 50% for all publications.  None of this work has been previously submitted for other qualifications.  No third party editorial assistance was provided.  The thesis is fewer than the maximum word limit in length.

Research paper thumbnail of The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy

Magnetic resonance spectroscopy (MRS) provides a non-invasive means of determining isocitrate deh... more Magnetic resonance spectroscopy (MRS) provides a non-invasive means of determining isocitrate dehydrogenase (IDH) status. Determination of 2-hydroxyglutarate (2-HG) presence through MRS is a means of determining IDH status; however, differences may be seen by grade. The goal of this paper is to perform a diagnostic test accuracy (DTA) meta-analysis on 2-HG MRS for IDH status in both lower-grade glioma (LGG) and glioblastoma (GBM) in preoperative patients. A systematic review and meta-analysis were performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Diagnostic Test Accuracy guidelines. Quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies 2. The search was up to date as of 09/02/2021. Nine English-language journal articles were included. The meta-analysis found a pooled sensitivity of 93% (95% CI 58–99%) and specificity of 84% (95% CI 51–96%) for LGG (n= 181). For GBM (n= 77), the pooled sensitivity wa...

Research paper thumbnail of Hypertrophic olivary degeneration: anatomy, aetiology and neuroimaging

Poster: "2017 ASM / R-0080 / Hypertrophic olivary degeneration: anatomy, aetiology and neuro... more Poster: "2017 ASM / R-0080 / Hypertrophic olivary degeneration: anatomy, aetiology and neuroimaging" by: "K. Ravindran, A. Lasocki, F. Gaillard; Melbourne/AU"

Research paper thumbnail of Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research

American Journal of Neuroradiology

There is a growing understanding of the prognostic importance of non-contrast-enhancing tumor in ... more There is a growing understanding of the prognostic importance of non-contrast-enhancing tumor in glioblastoma, and recent attempts at more aggressive management of this component using neurosurgical resection and radiosurgery have been shown to prolong survival. Optimizing these therapeutic strategies requires an understanding of the features that can distinguish non-contrast-enhancing tumor from other processes, in particular vasogenic edema; however, the limited and heterogeneous manner in which it has been defined in the literature limits clinical translation. This review covers pertinent literature on our growing understanding of non-contrast-enhancing tumor and focuses on key conventional MR imaging features for improving its delineation. Such features include subtle differences in the degree of FLAIR hyperintensity, gray matter involvement, and focal mass effect. Improved delineation of tumor from edema will facilitate more aggressive management of this component and potentially realize associated survival benefits.

Research paper thumbnail of Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)

Journal for ImmunoTherapy of Cancer

BackgroundMelanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity... more BackgroundMelanoma brain metastases (MBMs) are a challenging clinical problem with high morbidity and mortality. Although first-line dabrafenib–trametinib and ipilimumab–nivolumab have similar intracranial response rates (50%–55%), central nervous system (CNS) resistance to BRAF-MEK inhibitors (BRAF-MEKi) usually occurs around 6 months, and durable responses are only seen with combination immunotherapy. We sought to investigate the utility of ipilimumab–nivolumab after MBM progression on BRAF-MEKi and identify mechanisms of resistance.MethodsPatients who received first-line ipilimumab–nivolumab for MBMs or second/third line ipilimumab–nivolumab for intracranial metastases with BRAFV600 mutations with prior progression on BRAF-MEKi and MRI brain staging from March 1, 2015 to June 30, 2018 were included. Modified intracranial RECIST was used to assess response. Formalin-fixed paraffin-embedded samples of BRAFV600 mutant MBMs that were naïve to systemic treatment (n=18) or excised afte...

Research paper thumbnail of Clinical and radiological evolution of cerebral amyloid angiopathy-related inflammation in the context of anti-PD-1 immunotherapy

Research paper thumbnail of Correction to: Serum microRNA is a biomarker for post-operative monitoring in glioma

Journal of Neuro-Oncology

Research paper thumbnail of The Imaging of Immunotherapy-Related Hypophysitis and Other Pituitary Lesions in Oncology Patients

Research paper thumbnail of Serum microRNA is a biomarker for post-operative monitoring in glioma

Journal of Neuro-Oncology